Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Sep;89(3):557-563.
doi: 10.4269/ajtmh.12-0736. Epub 2013 Jul 15.

Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama

Clinical Trial

Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama

Néstor Sosa et al. Am J Trop Med Hyg. 2013 Sep.

Abstract

In this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin + 0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099). When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046). Both creams were well tolerated with mild application site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy against L. panamensis cutaneous leishmaniasis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Subject disposition. A total of 54 subjects were consented and screened of which 30 were randomized. All but one of the 30 subjects received 20 days application of study drug. One subject missed one day. Subjects who were withdrawn early from the study were withdrawn by the investigator as judged to be treatment failures: one subject in the WR 279,396 group and six subjects in the Paromomycin Alone group.
Figure 2.
Figure 2.
Example of response to treatment with WR 279,396. The subject presented with a deep ulcerous lesion surrounded by a large area of induration on the foot. At 1 week after completing treatment (Day 28), the induration had resolved and the ulcer was nearly completely cured. The ulcer completely cured by Day 42 and remained cured for the duration of follow-up.
Figure 3.
Figure 3.
Mean percentage cure rate over time for the index lesion. Index lesions start to completely re-epithelialize at Day 28 and continue to heal until about Day 100 after which time, if subjects had a lesion that did not cure; the subject was taken off study and offered other treatment. At Day 49 the curves for the two treatment groups start to separate with lesions treated with WR 279,396 ultimately reaching a higher final cure rate than that for the Paromomycin Alone group.

Comment in

  • Topical paromomycin and gentamicin for new world cutaneous leishmaniasis in Panama.
    Monge-Maillo B, López-Vélez R. Monge-Maillo B, et al. Am J Trop Med Hyg. 2014 Jun;90(6):1191. doi: 10.4269/ajtmh.14-0040a. Am J Trop Med Hyg. 2014. PMID: 24898981 Free PMC article. No abstract available.
  • In response.
    Grogl M, Sosa N, Kreishman-Deitrick M. Grogl M, et al. Am J Trop Med Hyg. 2014 Jun;90(6):1192. doi: 10.4269/ajtmh.14-0040b. Am J Trop Med Hyg. 2014. PMID: 24898982 Free PMC article. No abstract available.

References

    1. WHO Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO Technical Report Series. 2010:949.
    1. University of Texas Southwestern Medical Center Dermatologists Identify North Texas Leishmaniasis Outbreak. 2008. http://www.utsouthwestern.edu/utsw/cda/dept353744/files/411952.html New Release DALLAS—September 14, 2007. Available at. Accessed 15 August 2012.
    1. Pehoushek JE, Quinn DM, Crum WP. Cutaneous leishmaniasis in soldiers returning from deployment to Iraq. J Am Acad Dermatol. 2004;51:S125–S128. - PubMed
    1. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis. 2008;2:e313. - PMC - PubMed
    1. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356:2571–2581. - PubMed

Publication types